DRUG PRIOR AUTHORIZATION COMMITTEE MEETING

**June 16, 2016**

**Department of Natural Resources, LaCharette/Nightengale Conference Room, Jefferson City, MO**

|  |  |
| --- | --- |
| **Committee Members Present**Conrad Balcer, D.OGene Forrester, R.Pharm D Laine Young-Walker, M.D.Morgan Sperry, Pharm DJennifer Kemp-Cornelius, Pharm D  | MO HealthNet Staff Present:Mark Roaseau, R.Ph, Clinical PharmacistStephen Calloway, R.Ph, Director of PharmacyJenna McTeer, RNAngela Wilson, Manager, Band ILisa Smith, Medicaid SpecialistMegan Goldthrite, Administrative Office Support AssistantElizabeth Short, Medicaid SpecialistChristine Thompson, Fiscal Unit ManagerDr. Timothy Kling  |

**Contractors in Attendance:**

Katie Wilbers, Pharm D, Xerox

Josh Moore, Pharm D, Xerox

Luke Boehmer, Pharm D, Xerox

Rick Pope, Pharm D, Magellan

|  |
| --- |
| Others Attending: |
| Josh Moore, XeroxKatie Wilbers, XeroxJim Baumann, PfizerRandi Lewandowski, TevaReed Fontenot, FerringAaron Shaw, BIMike Donze, BIJason Klump, BIShelley Baugh, CelgencParry Midne, BI | Mary Rackers, AbbvieBoussad Aitchallal, AbbvieMike Holmes, Susovion PharmTim Ludlam, AllergonJason Lurk, Novo NordiskTodd Herman, MerckBerend Koops, MerckBrian Strickland, GileadEric Knisely, NovartisChristine Soltmli, Amgen | Susan Zalenski, J & JPhil King, PfizerAnnette Walther, WiproGeri Roling, WiproLon Lowry, NovatisLeeAnn Griffin, PfizerKen Ludwig, The Medicines Co.Jason Enders, Sonfi GenzymeLisa Tootle, BMSMelissa Laurie, BMS | Jennifer Stoffel, JanssenLuke Boehmer, XeroxStephanie Keithly, Novo NordiskEvan Rushing, AlkermesDonna Osterlurd, GenzymeGrant Calr`, BMSJennifer Wilbanks, OtsukaKathy Blecha, AstellasChuck Duckwasth, AstellasJeff Wills, Acorda |

Many names on the sign-in sheet were illegible. Sign-in sheet on file for review.

|  |  |
| --- | --- |
| **Welcome, Introductions and Opening Remarks** | Conrad Balcer, D.O., Acting Committee Chairman, called the meeting to order. Stephen Calloway introduced Christine Thompson, along with other MO HealthNet staff in attendance. Stephen also introduced Jennifer Kemp-Cornelius and advised there are still two open spots on the committee. Stephen then asked that the Hepatitis C be postponed until the next meeting. This was put to a vote, please see roll call votes.  |
| **Minutes Approval**  | Minutes of the March 17, 2016 meeting were reviewed and approved. Gene Forrester moved to accept the meeting minutes. Morgan Sperry seconded the motion. (See Roll Call Vote) |
| **Pharmacy Program/Budget Update** | Stephen Calloway presented a brief slideshow on behalf of Christine Thompson. The presentation contained graphs representing an expenditure amount per member for all eligible participants, disabled participants, elderly participants, and other; a pie chart of participants; and expenditures by participants. |
| **DUR Report** | Stephen Calloway stated all items from the April DUR Meeting were ratified and are scheduled to be implemented the 3rd quarter of 2016.  |
| **Old Business** |
| **Implementation Schedule**  | An updated copy of the Proposed Implementation Schedule for Edits, including PDL classes was included in the Members’ meeting packet and provided as a handout to all attending. The schedule included the therapeutic classes will be implemented October 2016. PDL decisions from June/July will be implemented October 2016. Schedules may be found on the MHD web page at <http://dss.missouri.gov/mhd/cs/pharmacy/impsched.pdf>  |
| **New Business** |
| **New Drug Review** | Stephen Calloway reviewed the new drug products that were identified for the quarter April, May, June 2016 and the recommended status within the clinical program.**• Discussion –** A listing of products recommended for open access, clinical edit, preferred drug list (PDL) product, or continued prior authorization was provided in the Members’ meeting packet for discussion and action. This listing was also provided as a handout to all attending. **• Public Hearing –** Garrard Buonpane from Tris Pharma provided information on Dyanaval XR, Phillip King from Pfizer provided information on Quilichew, Make Ferrari from Merk provided information on Zepitir.**• Decision –** Members voted to accept the new drug recommendations as presented. (See Roll Call Vote) |

|  |
| --- |
| **Clinical Edits** |
| **Entresto Clinical Edit** | **• Discussion –** Mr. Calloway reviewed the criteria document, and went over recommended approval and denial criteria. Mark Roseau and Conrad Balcer had a conversation regarding denial criteria. **• Public Hearing –** Evie Knisely from Novartis provided information on Entresto. **• Decision –** After discussion of proposed criteria the clinical edit was approved. (See Roll Call Vote) |
| **PCSK9 Inhibitors (Praluent/Repatha) Clinical Edit** | **• Discussion –** Mr. Calloway reviewed the criteria document, and went over recommended approval and denial criteria.**• Public Hearing –** No comments entered.**• Decision –** The Committee voted to accept this clinical edit as presented. (See Roll Call Vote) |
| **Xolair/Nucala Clinical Edit** | **• Discussion –** Mr. Calloway reviewed the criteria document, and went over recommended approval and denial criteria.**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this clinical edit as presented. (See Roll Call Vote) |
| **Preferred Drug List (PDL)** |
| **Amylin Analogs** | **• Discussion –** Mr. Calloway stated there are no changes recommended for this class.**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Antihyperuricemic Agents** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents**• Public Hearing –** No comments entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Bile Salts Agents** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents**• Public Hearing –** No comments entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Targeted Immune Modulators (formerly Biologics – Disease Modifying Anti-Rheumatic Drugs- DMARDs)** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents.**• Public Hearing –** No comments entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)**• Public Hearing –** Evie Knisely from Novartis provided information on Cosentyx, Phillip King from Pfizer provided information on Xeljanz and Xeljanz XR, Melissa Lauri from BMS provided information on Orencia, Ashley Polce from Abbvie provided information on Humera, Shelly Baugh from Celgene provided information non Otezla. **• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Bone Deossification Suppression Agents (including Calcitonin)**  | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents**• Public Hearing –** No comments entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **BPH Agents (formerly Androgen Hormone Inhibitors)** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents**• Public Hearing –** No comments entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Cryopyrin-Associated Periodic Syndrome (CAPS) Agents** | **• Discussion –** Mr. Calloway stated there are no changes recommended for this class.**• Public Hearing –** No comments entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **DPP-IV (Dipeptidyl Peptidase-4) Inhibitors**  | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Electrolyte Depleters (Phosphate Binders)** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Fluoroquinolones – Oral** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **GLP-1 Receptor Agonists (Anti-Diabetic Mimetics)** | **• Discussion –** Mr. Calloway stated there are no changes recommended for this class.**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Growth Hormones** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents**• Public Hearing –** Biran Patel from Novo Nordisk provided information on Norditropin. **• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Hematopoietic Agents** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Ribavirins** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Insulins** | **• Discussion –** Mr. Calloway stated there are no changes recommended for this class.**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Insulins – Long Acting** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents**• Public Hearing –** Jason Lurk from Novo Nordisk provided information on Tresiba. **• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Insulins – Mix** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents**• Public Hearing –** No comments entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Insulins – Rapid Acting** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Intravaginal Antibiotics** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Macrolides – Adult**  | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents**• Public Hearing –** No comments entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Macrolides – Pediatric**  | **• Discussion –** Mr. Calloway stated there are no changes recommended for this class.**• Public Hearing –** No comments entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Multiple Sclerosis (MS) Agents** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents**• Public Hearing –** Jason Enders from Sanofi provided information on Aubagio, Tanner Odom from Pfizer provided information on Plegridy, **• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Oral Anti-Diabetics: Alpha-Glucosidase Inhibitors** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Oral Anti-Diabetics: Biguanides** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Oral Anti-Diabetics: Combinations** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Oral Anti-Diabetics: Meglitinides** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Oral Anti-Diabetics: Sulfonylureas 2nd Generation** | **• Discussion –** Mr. Calloway stated there are no changes recommended for this class.**• Public Hearing –** No comments entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Oral Anti-Diabetics: Thiazolidinediones** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents**• Public Hearing –** Mike Donze from Boehringer Ingelheim provided information on Jardiance. **• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents**• Public Hearing –** Jennifer Stoffel from Jansen provided information on Invokana.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Tetracyclines** | **• Discussion –** Mr. Calloway stated there are no changes recommended for this class.**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Urinary Tract Antispasmodics** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents**• Public Hearing –** Kathy Blecha and Chuck Duckworth from Astellas provided information on Mybetriq. **• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Proposed New Preferred Drug Classes** |  |
| **Preferred Drug List Announcement** | A handout of therapeutic categories to be reviewed for inclusion on the Preferred Drug List for the next phase and meeting was included in the meeting packet. This handout was also provided to all attendees and will be posted to the Division's web page.  |
|  |  |
| **Xerox Update** | Luke Boehmer, PharmD reviewed clinical edits, utilization data and trends for ADHD. Also, spoke about the different reasons for denials.  |
| **Program Utilization:****Top 25 Drugs Summary** | Dr. Boehmer reviewed the Top 25 Drugs Summary Reports for the 4th quarter 2015 and the 1st quarter 2016. Two versions were presented: one report ranked drug spend by dollars and the other by utilization/claims. |
| **Call Center Statistics/****CyberAccess Reports** | A handout detailing pharmacy help desk call center activity was provided for all attending. Cyber Access Active User Counts and Logging Information reports detailing activity were shared. Dr. Boehmer reviewed how many sites/physical locations are trained and have access to CyberAccess. Reports also detailed the number and type of prescribers and active users on CyberAccess.  |
| **Adjourn** | The meeting was adjourned. The next meeting of the Drug Prior Authorization Committee is scheduled for Thursday, **September 15, 2016** at the **Department of Natural Resources, 1101 Riverside Drive, Lacharrette/Nightengale Rooms**. Attendees were advised to check the [calendar of events](http://www.dss.mo.gov/mhd/global/pages/calendar.htm) on the MHD website for meeting location changes over the next few months. (See attached roll call) |

**Roll Call Votes – June 16, 2016**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Member** | **Minutes** | **New Drug Review** | **I. Entresto Clinical Edit** | **PC SK9 Inhibitors (Praluent/Repatha)** | **Xolair/Nucala Clinical Edit** | **Amylin Analogs PDL** | **Bile Salt Agents** |
| **Conrad Balcer, D.O.** |  Y |  Y |  Y |  Y |  Y |  Y |  Y |
| **Pat Bryant, Pharm D** | - | - | - | - | - | - | - |
| **Gene Forrester, R.Ph** |  YM |  YM |  Y |  Y |  Y |  Y |  YM |
| **Laine Young-Walker, M.D.** |  Y |  Y2 |  Y2 |  YM |  YM |  YM |  Y |
| **Morgan Sperry, Pharm D** |  Y2 |  Y |  YM |  Y2 |  Y2 |  Y |  Y2 |
| **Jennifer Kemp-Cornelius**  |  Y |  Y |  Y |  Y |  Y |  Y2 |  Y |

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Member** | **DMARDS** | **Bone Deossification Suppression Agents** | **BPH agents** | **CAPS Agents** | **DDP - IV inhibitors** | **Electrolyte depleters** | **Fluoroquinolones** |
| **Conrad Balcer, D.O.** |  Y |  Y |  Y |  Y |  Y |  Y |  Y |
| **Pat Bryant, Pharm D** | - | - | - | - | - | - | - |
| **Gene Forrester, R.Ph** |  YM |  Y |  YM |  Y |  Y |  Y |  Y |
| **Laine Young-Walker, M.D.** |  Y |  YM |  Y |  YM |  Y |  YM |  YM |
| **Morgan Sperry, Pharm D** |  Y2 |  Y2 |  Y |  Y2 |  Y2 |  Y2 |  Y2 |
| **Jennifer Kemp-Cornelius**  |  Y |  Y |  Y2 |  Y |  YM |  Y |  Y |

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **GLP - 1 Receptors** | **Growth Hormones** | **Hematopoietic Agents** | **~~Hepatitis C Therapy~~** | **Ribavirins** | **Insulins** | **Insulins LA** |
| **Conrad Balcer, D.O.** |  Y |  Y |  Y |  Y |  Y |  Y |  Y |
| **Pat Bryant, Pharm D** | - | - | - | - | - | - | - |
| **Gene Forrester, R.Ph** |  Y2 |  YM |  Y2 |  Y |  YM |  YM |  YM |
| **Laine Young-Walker, M.D.** |  YM |  Y |  Y |  Y |  Y |  Y |  Y |
| **Morgan Sperry, Pharm D** |  Y |  Y2 |  YM |  Y |  Y |  Y2 |  Y2 |
| **Jennifer Kemp-Cornelius**  |  Y |  Y |  Y |  Y |  Y2 |  Y |  Y |

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Insulins Mix** | **Insulins RA** | **Intravaginal Antibiotics** | **Marcolides adult** | **Marcolides Ped** | **MS Agents** | **Oral antidiabetics: Alpha Glucosidase**  |
| **Conrad Balcer, D.O.** |  Y |  Y |  Y |  Y |  Y |  Y |  Y |
| **Pat Bryant, Pharm D** | - | - | - | - | - | - | - |
| **Gene Forrester, R.Ph** |  Y |  Y |  Y |  Y2 |  Y2 |  Y |  YM |
| **Laine Young-Walker, M.D.** |  Y2 |  Y |  Y2 |  Y |  Y |  YM |  Y |
| **Morgan Sperry, Pharm D** |  YM |  Y |  YM |  YM |  YM |  Y2 |  Y2 |
| **Jennifer Kemp-Cornelius**  |  Y |  Y |  Y |  Y |  Y |  Y |  Y |

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Oral Aintidiabetics Biguanides** | **Oral AntiDiabetics Combo** | **Oral AntiDiabetics Meglitinides** | **Oral AntiDiabetics Sulfonylureas** | **Oral Antidiabetics Thiazolidinediones** | **SGLT2 inhibitors** | **Tetracyclines** |
| **Conrad Balcer, D.O.** |  Y |  Y |  Y |  Y |  Y |  Y |  Y |
| **Pat Bryant, Pharm D** | - | - | - | - | - | - | - |
| **Gene Forrester, R.Ph** |  YM |  Y |  Y |  Y |  Y |  Y |  YM |
| **Laine Young-Walker, M.D.** |  Y |  Y |  Y |  Y |  Y |  YM |  Y |
| **Morgan Sperry, Pharm D** |  Y2 |  YM |  YM |  YM |  Y |  Y |  Y2 |
| **Jennifer Kemp-Cornelius**  |  Y |  Y2 |  Y2 |  Y2 |  Y |  Y2 |  Y |

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Urinary Tract Antispasmodics** | **Antihyperuricemic Agents** | **Agenda Change** | **Adjourn**  |  |  |  |
| **Conrad Balcer, D.O.** |  Y |  Y |  Y |  Y |   |  |   |
| **Pat Bryant, Pharm D** | - | - | - | - |   |  |   |
| **Gene Forrester, R.Ph** |  YM |  Y2 |  Y2 |  Y |   |  |   |
| **Laine Young-Walker, M.D.** |  Y |  Y |  Y |  Y |   |  |   |
| **Morgan Sperry, Pharm D** |  Y2 |  YM |  Y |  Y2 |   |  |   |
| **Jennifer Kemp-Cornelius**  |  Y |  Y |  YM |  YM |   |  |   |